Back to News & Events

CEWIT Medical Technologies and Healthcare Innovations Symposium

CEWIT, the Center for Biotechnology and Henry Schein, Inc., have joined forces to host an expert symposium presenting cutting-edge advances in biomedical and clinical-related technologies, digital health, and smart medical devices, focusing on the technology as well as the joint industry, academic, and R&D partnerships that are integral to major innovations in the healthtech domain — at Stony Brook University.

Tuesday, March 28, 2017, 9:30am-3:30pm
The Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University
1500 Stony Brook Road, Stony Brook, NY 11794-6040

Event is free but registration is requires. View full agenda and register here: www.cewit.org/events/healthtech.html

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 2062 [post_author] => 3 [post_date] => 2015-11-23 20:09:45 [post_date_gmt] => 2015-11-23 20:09:45 [post_content] => Biotechnology Strategist Brian McCarthy and Pharma Executive Gian Luca Araldi selected to launch new bioscience companies STONY BROOK, N.Y. – November 23, 2015 – The Center for Biotechnology at Stony Brook University announced today the appointment of Brian McCarthy, PhD and Gian Luca Araldi, PhD, as BioEntrepreneurs-In-Residence (B-EIR) for the Long Island Bioscience Hub.  The Long Island Bioscience Hub is a National Institutes of Health-designated Research Evaluation and Commercialization Hub, and represents a partnership between Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory, to commercialize technology emerging from their institutions. Drs. McCarthy and Araldi have broad bioscience industry experience and comprehensive knowledge of commercializing academic technologies. In their roles as BEIR they will identify technologies that have the potential to support company formation in the region.  Each brings unique skills and perspectives to technology assessment and bioscience-startups. Dr. McCarthy is a senior biotechnology strategist with operational, start-up, development, and financial expertise. He currently serves as a business advisor to Gismo Therapeutics Inc. and VP of Business and Clinical Development at Viatar CTC Solutions Inc. Prior to his Wall Street and entrepreneurial career, Dr. McCarthy was a faculty member at Cornell University Medical College and the National Naval Medical Center. Dr. McCarthy received his PhD in Neurobiology from Stony Brook University. Dr. Araldi is a pharmaceutical and biotechnology executive with more than 25 years of experience ranging from basic research through clinical development at major pharmaceutical companies including Glaxo, Forest Laboratories and Merck-Serono.  Dr. Araldi has been involved in the development of key medicines such as Teflaro®, Dutogliptin®, Gavestinel®, Sanfetrinem® and Sanfetrinem® Cilexetil and is the inventor of 113 granted patents. Dr. Araldi received doctorate degrees in Organic Chemistry and Pharmacy from the University of Parma (Italy) and recently received his M.B.A. in Finance from Long Island University Post. “The Long Island Bioscience Hub is excited to announce the appointments of Drs. McCarthy and Araldi as BioEntrepreneurs-in-Residence” Diane Fabel, Director of Operations for the Center for Biotechnology stated. “They join a talented roster of five existing BioEntrepreneurs in Residence at the Center for Biotechnology who are well on their way to commercializing technologies and building their companies.” As B-EIRs Drs. McCarthy and Araldi are tasked with identifying technology or technologies from within the partner institutions that will create the foundation for licensing and company formation.  They will have the support of the LIBH business and technology development staff, as well as the support of external industry advisors to develop successful commercialization strategies. The LIBH can also provide access to a competitive pool of technology development funding to help move their technologies down a commercial pathway.  Ultimately, the goal is to help the company position itself prepare for SBIR/STTR grant opportunities, and Angel and VC investment. [post_title] => Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-selects-bioentrepreneurs-in-residence [to_ping] => [pinged] => [post_modified] => 2016-03-29 20:13:28 [post_modified_gmt] => 2016-03-29 20:13:28 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2062 [menu_order] => 197 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2700 [post_author] => 4 [post_date] => 2017-05-19 18:26:24 [post_date_gmt] => 2017-05-19 18:26:24 [post_content] => Center for Biotechnology BioEntrepreneur-in-Residence and Founder and CEO of Traverse Biosciences, Joseph Scaduto, recently penned a powerful article discussing the importance of human capital to the growth and sustainability of New York’s bioscience ecosystem. "...the prospect of “jumping ship” into a new bioscience venture is not just risky, it is downright scary, if not financially impossible, exacerbated further by the frightening lack of alternative job opportunities in the high-probability event of failure. In my opinion, this seemingly insurmountable and geographic “barrier to entry,” defined by the comparatively excessive risk of bioentrepreneurship, is a primary reason why New York continues to struggle to develop, cultivate and grow a vibrant, dynamic and self-sustaining bioscience industry cluster." Read the full article here.   [post_title] => Getting Serious About BioEntrepreneurship in New York [post_excerpt] => "The prospect of “jumping ship” into a new bioscience venture is not just risky, it is downright scary, if not financially impossible, exacerbated further by the frightening lack of alternative job opportunities in the high-probability event of failure." [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => getting-serious-about-bioentrepreneurship-in-new-york [to_ping] => [pinged] => [post_modified] => 2017-08-08 15:53:19 [post_modified_gmt] => 2017-08-08 15:53:19 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2700 [menu_order] => 145 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2675 [post_author] => 3 [post_date] => 2017-04-26 14:28:05 [post_date_gmt] => 2017-04-26 14:28:05 [post_content] => The Center for Biotechnology is seeking one or more qualified and motivated high school /undergrad students interested in learning about and supporting technology development and commercialization of new biomedical innovations on behalf of the Long Island Bioscience Hub (LIBH). The LIBH is a National Institutes of Health-designated Research, Evaluation, and Commercialization Hub (REACH), one of only three such centers in the country. The LIBH supports the development and commercialization activities of its partner institutions including Stony Brook University, Cold Spring Harbor Laboratory, and Brookhaven National Laboratory. Candidates for the Fellowship will have completed their sophomore year in high school through junior year in undergraduate studies. Candidates should have a GPA of no less than a 3.0, and have an interest in exploring careers in a biomedical field. Interested candidates should send a one-page statement of interest detailing their academic accomplishments and describing what they would like to gain from the Fellowship experience, along with a transcript to: Kristina Duryea kristina.duryea@stonybrook.edu. Selection Process: Deadline for application materials is May 1 – June 2, 2017. Additional admissions procedures (including interviews, by telephone or in person) may be required. Notification: Applicants will generally be notified by June 9, 2017. One-two applicants are expected to be selected. [post_title] => Commercialization Fellowship for High School Students & Undergrads [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => commercialization-internship-2017 [to_ping] => [pinged] => [post_modified] => 2017-04-26 14:28:05 [post_modified_gmt] => 2017-04-26 14:28:05 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2675 [menu_order] => 149 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 259 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Long Island Bioscience Hub Selects Bioentrepreneurs-In-Residence

More Information

Getting Serious About BioEntrepreneurship in New York

More Information

Commercialization Fellowship for High School Students & Undergrads

More Information